Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230003/S008

Alinity m HR HPV

Abbott Molecular, Inc. · Decision date Sep 24, 2025

FDA DECISIONP230003/S008

What did the FDA approve?

FDA records P230003/S008 as a supplement to PMA P230003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 24, 2025.

FDA approval order statement

Approval for creating an Alinity m Systems Liner (Liner) as a containment device placed underneath the Alinity m System to catch fluids that may leak from the reagent storage and dispense portions of the instrument.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Microbiology
Decision date
Sep 24, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P230003/S008
Regulatory pathway
PMA supplement
Product code
MAQ
Decision code
APPR
Decision date
Sep 24, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

For the original device and its historical approval scope, see PMA P230003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230003 · Original PMA

    Alinity m HR HPV

  2. P230003/S008 received

    Application receipt date recorded by FDA.

  3. P230003/S008 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P230003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230003

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Molecular, Inc.PMA approvalNov 1, 2023FDA
Alinity m HR HPVP230003/S006
Abbott Molecular, Inc.PMA supplementSep 10, 2025FDA
Alinity m HR HPVP230003/S009
Abbott Molecular, Inc.PMA supplementOct 17, 2025FDA
Alinity m HR HPVP230003/S010
Abbott Molecular, Inc.PMA supplementJan 6, 2026FDA
Alinity m HR HPVP230003/S012
Abbott Molecular, Inc.PMA supplementFeb 24, 2026FDA
Alinity m HR HPVP230003/S011
Abbott Molecular, Inc.PMA supplementMar 12, 2026FDA
Alinity m HR HPVP230003/S013
Abbott Molecular, Inc.PMA supplementMay 15, 2026FDA
Alinity m HR HPVP230003/S016
Abbott Molecular, Inc.PMA supplementMay 19, 2026FDA
Alinity m HR HPVP230003/S017
Abbott Molecular, Inc.PMA supplementMay 28, 2026FDA
Abbott Molecular, Inc.PMA supplementJun 8, 2026FDA
Alinity m HR HPVP230003/S018
Abbott Molecular, Inc.PMA supplementJun 22, 2026FDA
Alinity m HR HPVP230003/S015
Abbott Molecular, Inc.PMA supplementJul 23, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Becton Dickinson and CompanyPMA supplementAug 19, 2026FDA
Becton Dickinson and CompanyPMA supplementAug 14, 2026FDA
cobas HPVP190028/S023
Roche Molecular Systems, Inc.PMA supplementJun 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Molecular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1300 E Touhy Ave., Des Plaines, IL, 60018

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records